SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally has traders focused on Starknets privacy and Bitcoin DeFi plans, alongside its STARK-based post-quantum security narrative. Bullish momentum and ecosystem optimism are tempered by concerns about token unlocks, selling pressure, and whether the move is a short-lived pump.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a recent price rebound, with traders debating whether the move can continue or give way to another pullback. Bulls point to Bittensors decentralized-AI ecosystem and subnet development, while cautious voices question adoption and near-term catalysts amid broader crypto and macro uncertainty.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows steep selloff is being tied to a weak housing markethigh mortgage rates and affordability pressures are weighing on transactionswith lowered guidance adding to concerns despite revenue growth. Bearish traders see further downside, while bulls argue the shares are oversold and point to growth in rentals, mortgages and AI-enabled products.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Attention centers on Compounds institutional-market push, including a reported launch, new leadership and investment plans, alongside anticipation for V4. Many traders are bullish on COMPs limited supply and potential breakout, while skeptics point to weak relative price action and concerns about protocol liquidity.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is drawing attention after a recent rise in trading activity, with traders comparing the companys Niemann-Pick franchise to IntraBios reported acquisition and arguing that Zevra may be undervalued; some speculate about a potential buyer, but no deal is confirmed. The discussion also points to the pending European re-examination and upcoming results, with views divided over regulatory prospects and the stocks gains.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being tied to the launch of confidential perpetual trading powered by Hyperliquid, with traders also highlighting the tokens AI-agent and cross-chain Intents narrative. The reaction is largely bullish, though some remain cautious about pullbacks and the earlier NEAR Intents exploit.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

A Brazilian federal appeals court restored Sigma Lithiums existing mining licenses, allowing operations to resume after a shutdown. Traders welcomed the restart, while noting that the plant expansion remains blocked pending a community-related survey, leaving legal and execution risks in focus.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Cathie Woods latest portfolio reshuffle, including ARKK trims to AMD, SpaceX and Alphabet alongside biotech buying elsewhere in ARKs funds, is prompting debate over her trade timing and track record; some traders are also pointing to ARKKs recent strength and breakout attempts.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rebound and consolidation are driving IBIT discussion, with many traders treating pullbacks as buying opportunities and anticipating further gains, while others warn that momentum could fade. The conversation is largely about Bitcoins direction rather than a confirmed IBIT-specific catalyst.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

Gold miners are drawing attention as traders assess whether GDXs correction is bottoming, with higher real yields and a stronger dollar cited as near-term pressure on gold and miners. Some see signs of a rebound and are buying dips, while others want confirmation and warn that the pullback may continue; longer-term bulls point to central-bank buying and concerns about debt and currency debasement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top stocks in news: Fractal, Manappuram, Aye, Ola Electric, AEL, GMR Airports, Auro Pharma

… Clothing, Saven Technologies, Aarti Pharmalabs , Kesar Terminals & … in Pune. Aurobindo Pharma : The pharma company’s subsidiary, … Zydus Lifesciences: The pharma company has received … operating models. Akums Drugs and Pharmaceuticals : The drugmaker reported …

Akums Drugs posts ₹1,160 Cr in Q3 FY26

Mumbai: CDMO Akums Drugs and Pharmaceuticals posted a revenue of Rs … Sanjeev Jain, MD, Akums Drugs and Pharmaceuticals . Published On Feb 14, 2026 …

Mars Appoints Manish Syag as Managing Director for its Pet Nutrition Business in India

New Delhi [India], February 14: Today, Mars, Incorporated announced the appointment of Manish Syag as Managing Director of its Pet Nutrition division in India. Manish will lead the business, home to some of the country's most trusted and pioneering pet food brands, including PEDIGREE®, WHISKAS®, SHEBA®, among others.

ETRe-Pharma Summit to Spotlight the Innovation Reckoning Reshaping India’s Pharma Future

… Equirus Capital, Akums Drugs and Pharmaceuticals Limited, METTLER … ); Praveen Rao Akkinepally ( AstraZeneca India); Dr. Mahesh … Emcure Pharmaceuticals Limited, exploring: Women in Pharma — From … and Ganpat Anchaliya ( Novartis Corporate Center, Hyderabad). …

India to Host the Eighteenth Edition of South Asia’s Largest Pharma Event

… showcase the complete pharmaceutical value chain— … Pharma Leaders Roundtable *Women in Pharma Roundtable *CPHI Pharma Awards * Pharma … Exhibit Top pharmaceutical companies participating … Oceanic Pharmachem , and Akums Drugs and Pharmaceuticals . Others …

SC Drops Criminal Charges Against P&G Director, But No Relief For Akums Drugs in Vicks Gel Case

… alleged distribution of expired drugs in Mumbai. The case … drug, manufactured by Akums Drugs and Pharmaceuticals and distributed by P … , including local distributors, Akums Drugs , P&G Ltd., … role in distribution of the drugs without supporting material. The …

Trading Radar For August 25: Yes Bank, Reliance Group, IDBI Bank, Titagarh Rail And Akums Drugs Shares On Investors’ Watchlist

Equity

InterGlobe Aviation and Max Healthcare Institute to replace Hero MotoCorp and IndusInd Bank in the Nifty 50 index, effective Sept. 30

Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals

New Delhi [India], August 9: Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. This quarter continued to display strong performance with healthy growth in Adj EBITDA and Adj PAT.

Mars and Instamart Expand Paw Protecc to Hyderabad and Chennai to Shield Homeless Pets from Monsoon Hardship

New Delhi, Delhi, India (NewsVoir) As the monsoon rains sweep across India, Mars, Incorporated, a global leader in pet care products and services and Instamart – India’s pioneering quick-commerce platform – have expanded their joint initiative, PAW PROTECC, to support homeless pets. PAW PROTECC is a first-of-its-kind intervention that installs mobile shelters exclusively built for […]

NPPA allows Torrent Pharma to make combination drug in its own site at same retail price

… NPPA) has allowed Torrent Pharmaceuticals to shift manufacturing facility for … at Sikkim from Akums Drugs and Pharmaceuticals Ltd. "The … instant case since Torrent Pharmaceuticals Ltd has applied for … , it noted. The drugs price regulator modified the …

Akums Drugs & Pharmaceuticals Ltd. engages in the manufacturing and marketing of pharmaceutical products and services. It operates through the following segments: Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment manages the formulation of research and development, preparation and regulatory filing of dossiers, manufacturing formulations on contract basis, job work and testing services. The API segment offers the manufacturing and sale of KSM, Intermediate, and API products. The Domestic Branded Formulations segment refers to the marketing of its branded formulations in the Indian market. The International Branded Formulation segment deals with the marketing of its branded formulations in the global market. The Trade Generic segment is involved in the supply its generic products in the Indian market. The company was founded by Sanjeev Jain and Sandeep Jain on April 19, 2004 and is headquartered in New Delhi, India.

Current Price	749.65
Prev Close	784.90
Open	780.80
Dividend Yield	0.21%
50-Day Moving Average	767.73
Beta	0.42
Avg. Volume	327,710.33
PE Ratio	39.46

52-Week High	848.00
52-Week Low	408.02
Market Capitalization	118.21B
EPS (Annual)	16.67
Price to Book	3.47
Revenue Per Employee	2.42M

Feed

News

Sentiment

Fundamentals

Info

AKUMS.NSE Fundamentals